A Randomized, Double-blind, Placebo-Controlled, Ascending Single-Dose Safety, Tolerability, and Pharmacokinetics Study of EDP-322 in Healthy Adult Volunteers.

Trial Profile

A Randomized, Double-blind, Placebo-Controlled, Ascending Single-Dose Safety, Tolerability, and Pharmacokinetics Study of EDP-322 in Healthy Adult Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Dec 2009

At a glance

  • Drugs EDP 322 (Primary)
  • Indications Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Enanta Pharmaceuticals
  • Most Recent Events

    • 07 Oct 2009 New source identified and integrated (ClinicalTrials.gov record no. NCT00989872).
    • 07 Oct 2009 Planned number of patients added (67) added as reported by ClinicalTrials.gov.
    • 07 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top